...
机译:由口服癌外泌体引发的致癌性上皮 - 间充质转变被抗EGFR抗体抗体抑制
Department of Dental Pharmacology Graduate School of Medicine Dentistry and Pharmaceutical;
Department of Dental Pharmacology Graduate School of Medicine Dentistry and Pharmaceutical;
Department of Dental Pharmacology Graduate School of Medicine Dentistry and Pharmaceutical;
Department of Dental Pharmacology Graduate School of Medicine Dentistry and Pharmaceutical;
Advanced Research Center for Oral and Craniofacial Sciences Graduate School of Medicine Dentistry;
Advanced Research Center for Oral and Craniofacial Sciences Graduate School of Medicine Dentistry;
Department of Oral and Maxillofacial Radiology Graduate School of Medicine Dentistry and;
Division of Molecular and Cellular Biology Department of Radiation Oncology Beth Israel Deaconess;
Department of Dental Pharmacology Graduate School of Medicine Dentistry and Pharmaceutical;
Department of Dental Pharmacology Graduate School of Medicine Dentistry and Pharmaceutical;
Exosome; Extracellular vesicle; Epithelial-mesenchymal transition; Epidermal growth factor receptor; Oral cancer; Head and neck cancer;
机译:由口服癌外泌体引发的致癌性上皮 - 间充质转变被抗EGFR抗体抗体抑制
机译:抗EGFR单克隆抗体治疗大肠癌:西妥昔单抗和帕尼单抗的开发
机译:GC1118是一种新型的抗EGFR抗体,与胃癌中的西替昔单抗相比,具有有效的KRAS突变抗肿瘤活性
机译:抗EGFR单克隆抗体乙酸中脱酰胺的鉴定与表征
机译:自分泌和旁碱基信号调节炎症乳腺癌中的乳腺癌干细胞和上皮 - 间充质转换
机译:外泌体介导的miR-155传递通过上皮-间质转化赋予口腔癌细胞顺铂化学耐药性
机译:抗EGFR抗体西汀昔单抗由口腔鳞状细胞癌分泌,改变EGF驱动的间充质转换
机译:针对癌症治疗的选定药物遗传学测试的系统评价:CYp2D6用于乳腺癌中的他莫昔芬,KRas用于结肠直肠癌中的抗EGFR抗体,以及BCR-aBL1用于慢性髓性白血病中的酪氨酸激酶抑制剂。技术评估报告